Unidade de Endocrinologia do Desenvolvimento, Disciplina de Endocrinologia, Departamento de Clínica Médica, Hospital das Clínicas, Faculdade de Medicina, Universidade São Paulo, São Paulo, SP, Brasil,
Unidade de Endocrinologia do Desenvolvimento, Disciplina de Endocrinologia, Departamento de Clínica Médica, Hospital das Clínicas, Faculdade de Medicina, Universidade São Paulo, São Paulo, SP, Brasil.
Arch Endocrinol Metab. 2022;66(4):541-550. doi: 10.20945/2359-3997000000493. Epub 2022 Jun 23.
Central adrenal insufficiency (CAI) is a life-threatening disorder. This occurs when ACTH production is insufficient, leading to low cortisol levels. Since corticosteroids are crucial to many metabolic responses under organic stress and inflammatory conditions, CAI recognition and prompt treatment are vital. However, the diagnosis of CAI is challenging. This is not only because its clinical presentation is usually oligosymptomatic, but also because the CAI laboratory investigation presents many pitfalls. Thus, the clarification of when to use each test could be helpful in many contexts. The CAI challenge is also involved in treatment: Several formulations of synthetic steroids exist, followed by the lack of a biomarker for glucocorticoid replacement. This review aims to access all available literature to synthesize important topics about who should investigate CAI, when it should be suspected, and how CAI must be treated.
原发性肾上腺皮质功能减退症(CAI)是一种危及生命的疾病。当 ACTH 产生不足导致皮质醇水平降低时,就会发生这种情况。由于皮质类固醇对于有机应激和炎症条件下的许多代谢反应至关重要,因此,CAI 的识别和及时治疗至关重要。然而,CAI 的诊断具有挑战性。这不仅是因为其临床表现通常为寡症状,还因为 CAI 的实验室检查存在许多陷阱。因此,阐明何时使用每种检查可能在许多情况下都有帮助。CAI 挑战也涉及治疗:存在多种合成类固醇制剂,其次缺乏糖皮质激素替代的生物标志物。本综述旨在查阅所有可用文献,以综合有关应调查 CAI 的人群、何时应怀疑 CAI 以及如何治疗 CAI 的重要主题。